Update on research and clinical translation on specific clinical areas: From bench to bedside: How insight in immune pathogenesis can lead to precision medicine of severe juvenile idiopathic arthritis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Giannini, 1992, Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.–U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group, N Engl J Med, 326, 1043, 10.1056/NEJM199204163261602
Brewer, 1980, Gold therapy in the management of juvenile rheumatoid arthritis, Arthritis Rheum, 23, 404, 10.1002/art.1780230403
Lindsley, 1981, Pharmacotherapy of juvenile rheumatoid arthritis, Pediatr Clin North Am, 28, 161, 10.1016/S0031-3955(16)33968-2
Brewer, 1986, Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.–U.S.S.R. double-blind placebo-controlled trial, N Engl J Med, 314, 1269, 10.1056/NEJM198605153142001
Chan, 2010, Methotrexate–how does it really work?, Nat Rev Rheumatol, 6, 175, 10.1038/nrrheum.2010.5
Dinarello, 1993, Anticytokine strategies in the treatment of the systemic inflammatory response syndrome, J Am Med Assoc, 269, 1829, 10.1001/jama.1993.03500140081040
Martini, 2012, Systemic juvenile idiopathic arthritis, Autoimmun Rev, 12, 56, 10.1016/j.autrev.2012.07.022
Mellins, 2011, Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions, Nat Rev Rheumatol, 7, 416, 10.1038/nrrheum.2011.68
Date, 1999, Identification of a genetic risk factor for systemic juvenile rheumatoid arthritis in the 5'-flanking region of the TNF alpha gene and HLA genes, Arthritis Rheum, 42, 2577, 10.1002/1529-0131(199912)42:12<2577::AID-ANR10>3.0.CO;2-O
De Benedetti, 2003, Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 48, 1398, 10.1002/art.10882
Donn, 2001, A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 44, 1782, 10.1002/1529-0131(200108)44:8<1782::AID-ART314>3.0.CO;2-#
Fife, 2006, Novel IL10 gene family associations with systemic juvenile idiopathic arthritis, Arthritis Res Ther, 8, R148, 10.1186/ar2041
Fishman, 1998, The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis, J Clin Invest, 102, 1369, 10.1172/JCI2629
Moller, 2010, IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA), Clin Exp Rheumatol, 28, 912
Ogilvie, 2003, The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families, Arthritis Rheum, 48, 3202, 10.1002/art.11300
Omoyinmi, 2012, Association of the IL-10 gene family locus on chromosome 1 with juvenile idiopathic arthritis (JIA), PLoS One, 7, e47673, 10.1371/journal.pone.0047673
Barnes, 2009, Subtype-specific peripheral blood gene expression profiles in recent-onset juvenile idiopathic arthritis, Arthritis Rheum, 60, 2102, 10.1002/art.24601
Fall, 2007, Gene expression profiling of peripheral blood from patients with untreated new-onset systemic juvenile idiopathic arthritis reveals molecular heterogeneity that may predict macrophage activation syndrome, Arthritis Rheum, 56, 3793, 10.1002/art.22981
Hinze, 2010, Immature cell populations and an erythropoiesis gene-expression signature in systemic juvenile idiopathic arthritis: implications for pathogenesis, Arthritis Res Ther, 12, R123, 10.1186/ar3061
Ogilvie, 2007, Specific gene expression profiles in systemic juvenile idiopathic arthritis, Arthritis Rheum, 56, 1954, 10.1002/art.22644
McDermott, 2004, A common pathway in periodic fever syndromes, Trends Immunol, 25, 457, 10.1016/j.it.2004.07.007
Frosch, 2009, The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1beta form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 60, 883, 10.1002/art.24349
Gattorno, 2008, The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 58, 1505, 10.1002/art.23437
Pascual, 2005, Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade, J Exp Med, 201, 1479, 10.1084/jem.20050473
Allantaz, 2007, Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade, J Exp Med, 204, 2131, 10.1084/jem.20070070
Pascual, 2008, How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets, Immunol Rev, 223, 39, 10.1111/j.1600-065X.2008.00643.x
Macaubas, 2010, Distribution of circulating cells in systemic juvenile idiopathic arthritis across disease activity states, Clin Immunol, 134, 206, 10.1016/j.clim.2009.09.010
Grom, 2004, Natural killer cell dysfunction: a common pathway in systemic-onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis?, Arthritis Rheum, 50, 689, 10.1002/art.20198
Villanueva, 2005, Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome, Arthritis Res Ther, 7, R30, 10.1186/ar1453
Wulffraat, 2003, Reduced perforin expression in systemic juvenile idiopathic arthritis is restored by autologous stem-cell transplantation, Rheumatology (Oxford), 42, 375, 10.1093/rheumatology/keg074
Masters, 2009, Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*), Annu Rev Immunol, 27, 621, 10.1146/annurev.immunol.25.022106.141627
Guma, 2009, Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation, Arthritis Rheum, 60, 3642, 10.1002/art.24959
Cazzola, 1996, Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis, Blood, 87, 4824, 10.1182/blood.V87.11.4824.bloodjournal87114824
De Benedetti, 1991, Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis, Arthritis Rheum, 34, 1158, 10.1002/art.1780340912
De Benedetti, 1994, Serum soluble interleukin 6 (IL-6) receptor and IL-6/soluble IL-6 receptor complex in systemic juvenile rheumatoid arthritis, J Clin Invest, 93, 2114, 10.1172/JCI117206
De Benedetti, 2001, Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis, Endocrinology, 142, 4818, 10.1210/endo.142.11.8511
De Benedetti, 2012, Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis, N Engl J Med, 367, 2385, 10.1056/NEJMoa1112802
Yokota, 2004, Effective application of anti-IL-6-monoclonal antibody for children with systemic-onset juvenile idiopathic arthritis, Nihon Rinsho Meneki Gakkai Kaishi, 27, 22, 10.2177/jsci.27.22
Yokota, 2005, Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 52, 818, 10.1002/art.20944
Yokota, 2008, Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial, Lancet, 371, 998, 10.1016/S0140-6736(08)60454-7
Dinarello, 1999, IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family, J Allergy Clin Immunol, 103, 11, 10.1016/S0091-6749(99)70518-X
Dinarello, 2000, Interleukin-18, a proinflammatory cytokine, Eur Cytokine Netw, 11, 483
Dinarello, 2007, Interleukin-18 and the pathogenesis of inflammatory diseases, Semin Nephrol, 27, 98, 10.1016/j.semnephrol.2006.09.013
Dinarello, 1998, Overview of interleukin-18: more than an interferon-gamma inducing factor, J Leukoc Biol, 63, 658, 10.1002/jlb.63.6.658
Leung, 2001, A role for IL-18 in neutrophil activation, J Immunol, 167, 2879, 10.4049/jimmunol.167.5.2879
de Jager, 2007, Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study, Ann Rheum Dis, 66, 589, 10.1136/ard.2006.061853
Jelusic, 2007, Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis, Clin Rheumatol, 26, 1332, 10.1007/s10067-006-0474-0
Lotito, 2007, Interleukin 18 as a marker of disease activity and severity in patients with juvenile idiopathic arthritis, J Rheumatol, 34, 823
Maeno, 2002, Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al, Arthritis Rheum, 46, 2539, 10.1002/art.10389
Maeno, 2004, Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome, Arthritis Rheum, 50, 1935, 10.1002/art.20268
Shimizu, 2013, Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles, Cytokine, 61, 345, 10.1016/j.cyto.2012.11.025
Vastert, 2014, Effectiveness of first line use of recombinant IL-1RA treatment in steroid naive systemic juvenile idiopathic arthritis: results of a prospective cohort study, Arthritis Rheum, 66, 1034, 10.1002/art.38296
McInnes, 2000, Interleukin 18: a pleiotropic participant in chronic inflammation, Immunol Today, 21, 312, 10.1016/S0167-5699(00)01648-0
Grom, 2003, Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome, J Pediatr, 142, 292, 10.1067/mpd.2003.110
de Jager, 2009, Defective phosphorylation of interleukin-18 receptor beta causes impaired natural killer cell function in systemic-onset juvenile idiopathic arthritis, Arthritis Rheum, 60, 2782, 10.1002/art.24750
Grom, 1996, Macrophage activation syndrome in systemic juvenile rheumatoid arthritis, J Pediatr, 129, 630, 10.1016/S0022-3476(96)70140-3
Ravelli, 2002, Macrophage activation syndrome, Curr Opin Rheumatol, 14, 548, 10.1097/00002281-200209000-00012
Ravelli, 2012, Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment, Genes Immun, 13, 289, 10.1038/gene.2012.3
Janka, 2012, Familial and acquired hemophagocytic lymphohistiocytosis, Annu Rev Med, 63, 233, 10.1146/annurev-med-041610-134208
Behrens, 2007, Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis, J Rheumatol, 34, 1133
Rigante, 2007, First report of macrophage activation syndrome in hyperimmunoglobulinemia D with periodic fever syndrome, Arthritis Rheum, 56, 658, 10.1002/art.22409
Zhang, 2008, Macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms, Arthritis Rheum, 58, 2892, 10.1002/art.23734
Nold-Petry, 2010, Failure of interferon gamma to induce the anti-inflammatory interleukin 18 binding protein in familial hemophagocytosis, PLoS One, 5, e8663, 10.1371/journal.pone.0008663
Takada, 1999, Oversecretion of IL-18 in haemophagocytic lymphohistiocytosis: a novel marker of disease activity, Br J Haematol, 106, 182, 10.1046/j.1365-2141.1999.01504.x
Takada, 2001, Interleukin-18 in hemophagocytic lymphohistiocytosis, Leuk Lymphoma, 42, 21, 10.3109/10428190109097673
Quartier, 2011, A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial), Ann Rheum Dis, 70, 747, 10.1136/ard.2010.134254
Nigrovic, 2011, Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series, Arthritis Rheum, 63, 545, 10.1002/art.30128
Lequerre, 2008, Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France, Ann Rheum Dis, 67, 302, 10.1136/ard.2007.076034
Guo, 2009, IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells, Proc Natl Acad Sci U S A, 106, 13463, 10.1073/pnas.0906988106
Gracie, 1999, A proinflammatory role for IL-18 in rheumatoid arthritis, J Clin Invest, 104, 1393, 10.1172/JCI7317
Leung, 2000, Combined effects of IL-12 and IL-18 on the induction of collagen-induced arthritis, J Immunol, 164, 6495, 10.4049/jimmunol.164.12.6495
Wei, 2001, Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18, J Immunol, 166, 517, 10.4049/jimmunol.166.1.517
Nistala, 2008, Interleukin-17-producing T cells are enriched in the joints of children with arthritis, but have a reciprocal relationship to regulatory T cell numbers, Arthritis Rheum, 58, 875, 10.1002/art.23291
Nistala, 2009, Th17 and regulatory T cells: rebalancing pro- and anti-inflammatory forces in autoimmune arthritis, Rheumatology (Oxford), 48, 602, 10.1093/rheumatology/kep028
Koenen, 2008, Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells, Blood, 112, 2340, 10.1182/blood-2008-01-133967
Holzinger, 2012, The toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemic-onset juvenile idiopathic arthritis, Ann Rheum Dis, 71, 974, 10.1136/annrheumdis-2011-200598
Wynne-Roberts, 1978, Light- and electron-microscopic findings of juvenile rheumatoid arthritis synovium: comparison with normal juvenile synovium, Semin Arthritis Rheum, 7, 287, 10.1016/0049-0172(78)90027-6
Wedderburn, 1999, Molecular fingerprinting reveals non-overlapping T cell oligoclonality between an inflamed site and peripheral blood, Int Immunol, 11, 535, 10.1093/intimm/11.4.535
Silverman, 1993, Synovial fluid cells in juvenile arthritis: evidence of selective T cell migration to inflamed tissue, Clin Exp Immunol, 91, 90, 10.1111/j.1365-2249.1993.tb03360.x
Murray, 1996, Immunohistological characteristics of T cell infiltrates in different forms of childhood onset chronic arthritis, J Rheumatol, 23, 2116
Bywaters, 1977, Pathologic aspects of juvenile chronic polyarthritis, Arthritis Rheum, 20, 271
Wehrens, 2012, T cells out of control-impaired immune regulation in the inflamed joint, Nat Rev Rheumatol, 9, 34, 10.1038/nrrheum.2012.149
Olivito, 2009, Th17 transcription factor RORC2 is inversely correlated with FOXP3 expression in the joints of children with juvenile idiopathic arthritis, J Rheumatol, 36, 2017, 10.3899/jrheum.090066
Cosmi, 2011, Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis, Arthritis Rheum, 63, 2504, 10.1002/art.30332
Sakaguchi, 1995, Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases, J Immunol, 155, 1151, 10.4049/jimmunol.155.3.1151
Sakaguchi, 2006, Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease, Immunol Rev, 212, 8, 10.1111/j.0105-2896.2006.00427.x
de Kleer, 2004, CD4+CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis, J Immunol, 172, 6435, 10.4049/jimmunol.172.10.6435
de Kleer, 2003, The spontaneous remission of juvenile idiopathic arthritis is characterized by CD30+ T cells directed to human heat-shock protein 60 capable of producing the regulatory cytokine interleukin-10, Arthritis Rheum, 48, 2001, 10.1002/art.11174
van Loosdregt, 2010, Regulation of Treg functionality by acetylation-mediated Foxp3 protein stabilization, Blood, 115, 965, 10.1182/blood-2009-02-207118
van Loosdregt, 2013, Canonical Wnt signaling negatively modulates regulatory T cell function, Immunity, 39, 298, 10.1016/j.immuni.2013.07.019
van Loosdregt, 2013, Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity, Immunity, 39, 259, 10.1016/j.immuni.2013.05.018
Beukelman, 2011, 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features, Arthritis Care Res (Hoboken ), 63, 465, 10.1002/acr.20460
Dueckers, 2012, Evidence and consensus based GKJR guidelines for the treatment of juvenile idiopathic arthritis, Clin Immunol, 142, 176, 10.1016/j.clim.2011.10.003
Genestier, 1998, Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells, J Clin Invest, 102, 322, 10.1172/JCI2676
Cronstein, 2010, How does methotrexate suppress inflammation?, Clin Exp Rheumatol, 28, S21
Cronstein, 1993, The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation, J Clin Invest, 92, 2675, 10.1172/JCI116884
Cronstein, 1995, The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism, Br J Rheumatol, 34, 30, 10.1093/rheumatology/XXXIV.suppl_4.30
Cutolo, 2001, Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis, Ann Rheum Dis, 60, 729, 10.1136/ard.60.8.729
Montesinos, 2003, Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68, Arthritis Rheum, 48, 240, 10.1002/art.10712
Montesinos, 2007, The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5'-nucleotidase: findings in a study of ecto-5'-nucleotidase gene-deficient mice, Arthritis Rheum, 56, 1440, 10.1002/art.22643
Borsellino, 2007, Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression, Blood, 110, 1225, 10.1182/blood-2006-12-064527
Deaglio, 2007, Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression, J Exp Med, 204, 1257, 10.1084/jem.20062512
Dwyer, 2007, CD39 and control of cellular immune responses, Purinergic Signal, 3, 171, 10.1007/s11302-006-9050-y
Fletcher, 2009, CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis, J Immunol, 183, 7602, 10.4049/jimmunol.0901881
Moncrieffe, 2010, High expression of the ectonucleotidase CD39 on T cells from the inflamed site identifies two distinct populations, one regulatory and one memory T cell population, J Immunol, 185, 134, 10.4049/jimmunol.0803474
Otten, 2011, Factors associated with treatment response to etanercept in juvenile idiopathic arthritis, J Am Med Assoc, 306, 2340, 10.1001/jama.2011.1671
Brennan, 1989, Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis, Lancet, 2, 244, 10.1016/S0140-6736(89)90430-3
Feldmann, 2004, The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis, Best Pract Res Clin Rheumatol, 18, 59, 10.1016/j.berh.2003.09.010
Lovell, 2000, Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group, N Engl J Med, 342, 763, 10.1056/NEJM200003163421103
Lovell, 2008, Adalimumab with or without methotrexate in juvenile rheumatoid arthritis, N Engl J Med, 359, 810, 10.1056/NEJMoa0706290
Ruperto, 2007, A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis, Arthritis Rheum, 56, 3096, 10.1002/art.22838
Nadkarni, 2007, Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta, J Exp Med, 204, 33, 10.1084/jem.20061531
Ehrenstein, 2004, Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy, J Exp Med, 200, 277, 10.1084/jem.20040165
Valencia, 2006, TNF downmodulates the function of human CD4+CD25hi T-regulatory cells, Blood, 108, 253, 10.1182/blood-2005-11-4567
Tak, 2011, Advances in rheumatology: new targeted therapeutics, Arthritis Res Ther, 13, S5, 10.1186/1478-6354-13-S1-S5
Wehrens, 2013, Anti-tumor necrosis factor alpha targets protein kinase B/c-Akt-induced resistance of effector cells to suppression in juvenile idiopathic arthritis, Arthritis Rheum, 65, 3279, 10.1002/art.38132
de Kleer, 2004, Autologous stem cell transplantation for refractory juvenile idiopathic arthritis: analysis of clinical effects, mortality, and transplant related morbidity, Ann Rheum Dis, 63, 1318, 10.1136/ard.2003.017798
Wulffraat, 1999, Autologous haemopoietic stem-cell transplantation in four patients with refractory juvenile chronic arthritis, Lancet, 353, 550, 10.1016/S0140-6736(98)05399-9
Brinkman, 2007, Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial, Arthritis Rheum, 56, 2410, 10.1002/art.22656
Delemarre, 2011, Restoration of the immune balance by autologous bone marrow transplantation in juvenile idiopathic arthritis, Curr Stem Cell Res Ther, 6, 3, 10.2174/157488811794480726
Delemarre, 2014, Brief report: autologous stem cell transplantation restores immune tolerance in experimental arthritis by renewal and modulation of the teff cell compartment, Arthritis Rheumatol, 66, 350, 10.1002/art.38261
Evans, 2009, In vivo activated monocytes from the site of inflammation in humans specifically promote Th17 responses, Proc Natl Acad Sci U S A, 106, 6232, 10.1073/pnas.0808144106
Gattorno, 2007, Distinct expression pattern of IFN-alpha and TNF-alpha in juvenile idiopathic arthritis synovial tissue, Rheumatology (Oxford), 46, 657, 10.1093/rheumatology/kel346
van Amelsfort, 2007, Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis, Arthritis Rheum, 56, 732, 10.1002/art.22414
Nistala, 2010, Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment, Proc Natl Acad Sci U S A, 107, 14751, 10.1073/pnas.1003852107
Zonneveld-Huijssoon, 2012, TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis, Ann Rheum Dis, 71, 1706, 10.1136/annrheumdis-2011-201131
Zonneveld-Huijssoon, 2011, Bystander suppression of experimental arthritis by nasal administration of a heat shock protein peptide, Ann Rheum Dis, 70, 2199, 10.1136/ard.2010.136994
Miettunen, 2013, Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study, Ann Rheum Dis, 72, 1503, 10.1136/annrheumdis-2012-201937
Bakker, 2012, Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial, Ann Intern Med, 156, 329, 10.7326/0003-4819-156-5-201203060-00004
Mottonen, 2002, Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic drug therapy in early rheumatoid arthritis, Arthritis Rheum, 46, 894, 10.1002/art.10135
Rantalaiho, 2012, Long-term results of the FIN-RACo trial; treatment with a combination of traditional disease-modifying anti-rheumatic drugs is an excellent option in early rheumatoid arthritis, Clin Exp Rheumatol, 30, S27
Wallace, 2012, Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis, Arthritis Rheum, 64, 2012, 10.1002/art.34343
Tynjala, 2011, Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial, Ann Rheum Dis, 70, 1605, 10.1136/ard.2010.143347
Foell, 2010, Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial, J Am Med Assoc, 303, 1266, 10.1001/jama.2010.375